Friedel A, Prante O, Maschauer S
Cancers (Basel). 2024; 16(15).
PMID: 39123367
PMC: 11311842.
DOI: 10.3390/cancers16152639.
Keigley Q, Fowler A, OBrien S, Dehdashti F
Cancer J. 2024; 30(3):142-152.
PMID: 38753748
PMC: 11101139.
DOI: 10.1097/PPO.0000000000000715.
Tejeria M, Pereira M, Gambini J, Duarte P, Giglio J, Rey A
Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543174
PMC: 10975010.
DOI: 10.3390/ph17030388.
Kalaba P, Sanchez de la Rosa C, Moller A, Alewood P, Muttenthaler M
J Med Chem. 2024; 67(3):1625-1640.
PMID: 38235665
PMC: 10859963.
DOI: 10.1021/acs.jmedchem.3c01089.
Kairemo K, Hodolic M
Int J Mol Sci. 2023; 24(9).
PMID: 37175938
PMC: 10179508.
DOI: 10.3390/ijms24098235.
Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.
Parent E, Fowler A
J Endocr Soc. 2023; 7(3):bvac197.
PMID: 36655003
PMC: 9838808.
DOI: 10.1210/jendso/bvac197.
Diagnostic and Prognostic Role of F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept.
Fiz F, Bottoni G, Treglia G, Trimboli P, Piccardo A
J Clin Med. 2022; 11(13).
PMID: 35806878
PMC: 9267420.
DOI: 10.3390/jcm11133589.
PET Imaging of Estrogen Receptors Using F-Based Radioligands.
Kumar M, Salem K, Jeffery J, Fowler A
Methods Mol Biol. 2022; 2418:129-151.
PMID: 35119664
DOI: 10.1007/978-1-0716-1920-9_9.
Examining the evolving utility of FDG-PET/CT in breast cancer recurrence.
Djassemi N, Rampey S, Motiani J
Transl Cancer Res. 2022; 9(Suppl 1):S116-S121.
PMID: 35117953
PMC: 8797355.
DOI: 10.21037/tcr.2019.07.07.
[F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma.
Orevi M, Shamni O, Zalcman N, Chicheportiche A, Mordechai A, Moscovici S
Neurooncol Adv. 2021; 3(1):vdab019.
PMID: 33738450
PMC: 7954111.
DOI: 10.1093/noajnl/vdab019.
Evaluation of estrogen expression of breast cancer using F-FES PET CT-A novel technique.
Seenu V, Sharma A, Kumar R, Suhani S, Prashanth A, Mathur S
World J Nucl Med. 2020; 19(3):233-239.
PMID: 33354178
PMC: 7745867.
DOI: 10.4103/wjnm.WJNM_71_19.
PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.
Katzenellenbogen J
Cancers (Basel). 2020; 12(8).
PMID: 32718075
PMC: 7465097.
DOI: 10.3390/cancers12082020.
Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using F-FES and F-4FMFES PET Imaging.
Paquette M, Phoenix S, Lavallee E, Rousseau J, Guerin B, Turcotte E
Mol Imaging Biol. 2020; 22(5):1403-1413.
PMID: 32699974
PMC: 8080271.
DOI: 10.1007/s11307-020-01520-w.
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Jones E, Hathi D, Freimanis R, Mukhtar R, Jo Chien A, Esserman L
Cancers (Basel). 2020; 12(6).
PMID: 32527022
PMC: 7352259.
DOI: 10.3390/cancers12061511.
The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.
Katzenellenbogen J
Nucl Med Biol. 2020; 92:24-37.
PMID: 32229068
PMC: 7442693.
DOI: 10.1016/j.nucmedbio.2020.02.007.
Ring opening of epoxides with [F]FeF species to produce [F]fluorohydrin PET imaging agents.
Verhoog S, Brooks A, Winton W, Viglianti B, Sanford M, Scott P
Chem Commun (Camb). 2019; 55(45):6361-6364.
PMID: 31062010
PMC: 6542722.
DOI: 10.1039/c9cc02779c.
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
Jones E, Ray K, Li W, Chien A, Mukhtar R, Esserman L
NPJ Breast Cancer. 2019; 5:12.
PMID: 31016232
PMC: 6467896.
DOI: 10.1038/s41523-019-0107-9.
The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).
Vaidya T, Agrawal A, Mahajan S, Thakur M, Mahajan A
Mol Diagn Ther. 2018; 23(1):1-26.
PMID: 30411216
DOI: 10.1007/s40291-018-0366-4.
Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.
Salem K, Kumar M, Kloepping K, Michel C, Yan Y, Fowler A
Am J Nucl Med Mol Imaging. 2018; 8(2):119-126.
PMID: 29755845
PMC: 5944827.
Receptor Occupancy Imaging Studies in Oncology Drug Development.
Burvenich I, Parakh S, Parslow A, Lee S, Gan H, Scott A
AAPS J. 2018; 20(2):43.
PMID: 29520671
DOI: 10.1208/s12248-018-0203-z.